Archive for the Home Page Category

Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments

Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments

Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments

BEDFORD, Texas, April 19, 2021 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced an expansion of its Clinical Advisory Board with the appointment of four new members.

“We are honored to have such distinguished clinical experts in retinal disorders join us as advisers. Their guidance will be invaluable as we pioneer gene therapies to reprogram retinal cells and make them functionally active to regain vision,” said Nanoscope President and Co-Founder Samarendra Mohanty, Ph.D.

The four new members include:

  • Michael Singer, M.D., Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas. He is also the Director of Clinical Research at Medical Center Ophthalmology Associates in San Antonio.
  • Stephen H. Tsang, M.D, Ph.D., the Laszlo T. Bito Professor of Ophthalmology, and Pathology and Cell Biology at Columbia University Irving Medical Center.
  • Paul Yang, M.D., Ph.D., Assistant Professor in Ophthalmic Genetics and Immunology at the Oregon Health & Science University Casey Eye Institute.
  • SriniVas R. Sadda, M.D., President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles David Geffen School of Medicine.

The new members have joined current advisory board members: Samuel Barone,M.D.; Vittorio Porciatti, DSc; Weldon Wright, M.D.; and Thomas Yorio, Ph.D.

Nanoscope’s lead product is an optogenetic gene therapy, vMCO-010, that delivers light-sensitive Multi-Characteristics Opsin (MCO) into retinal cells to restore vision in patients with retinitis pigmentosa (RP) and Stargardt disease. Both applications have received orphan drug designation from the FDA. If successful, the optogenetic therapy would be the first treatment aimed at correcting these conditions.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics, of Bedford, TX, is advancing gene therapy using light-sensitive molecules for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope utilizes an ambient light-sensitive MCO molecule to re-sensitize the retina toward ambient light level. The company’s pipeline includes optogenetics based retinal regeneration therapy for vision restoration in patients with RP, Stargardt disease, and dry/end-stage wet age-related macular degeneration (AMD). For more information visit: https://nanostherapeutics.com/

 

 

Contact:
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716

Charles Craig
Opus Biotech Communications
charles.s.craig@gmail.com
404-245-0591

Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health

Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health

Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health

BEDFORD, Texas, Feb. 2, 2021 /PRNewswire/ — To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers® in collaboration with University of Colorado, and Miami University were recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).  https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-initiatives/3-d-retina-organoid-challenge-3-d-roc/2017-ideation-challenge/2017-ideation-winner-and-honorable-mention

The organoids provide a unique opportunity for evaluating novel gene therapies including Multi-Characteristic Opsin (MCO) gene therapy for vision restoration. This is an active therapeutic development area for Nanoscope Therapeutics to evaluate effectiveness of MCO optogenetic therapy, which has shown promise in restoring sight in blind subjects. The opsin-based (and other gene therapy) treatment requires evaluation of potency in-vitro (for release characterization of drug) and objective clinical measurements. While we are currently using fluorescence imaging for objective measurement of potency of MCO-drug, there is a need for label-free evaluation of light activated activities in opsin-sensitized neurons. This is especially important because fluorescence methods inherently perturb the light-sensitive opsin-expressing neurons.

“Nanoscope continue to develop breakthrough technologies to assess neural activities without use of excitation light (as used in fluorescence) and is currently working on implementing this approach for objective label-free detection of activities of natural photoreceptors of eye as well as opsin-sensitized cellular activities in response to light stimulation in-vivo,” said Samarendra Mohanty, PhD, President and Chief Scientific Officer.

For the 3D ROC challenge, Nanoscope used near-infrared light-based Optical Coherence Tomography (OCT) integrated with electro and opto-physiology device to measure both structure and function of layer-specific cells in the targeted regions of retina.
https://www.youtube.com/watch?v=Gh0IqFZV_I0&list=LL&index=3&t=19s

This label-free activity detection technology has already attracted several Biopharmaceutical companies to evaluate their therapeutic approaches.

“We are also advancing OCT guided targeted laser microirradiation technology for creating models of degenerative eye diseases such as Retinitis Pigmentosa (RP) and dry age-related macular degeneration (dry-AMD) as well as for targeted delivery of therapeutic genes,” said Sulagna Bhattacharya, CEO of Nanoscope.  

About NANOSCOPE THERAPEUTICS Inc.

Nanoscope Therapeutics is advancing gene therapy using light-sensitive MCO-molecules for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Our pipeline includes optogenetics based retinal regeneration therapy for vision restoration in patients with RP, Stargardt disease, and dry-AMD.

Contact:

Sulagna Bhattacharya
Investor Relations and Corporate Communications
817-719-2692
info@nanostherapeutics.com

Nanoscope Therapeutics, Inc.
1312 Brown Trail, Suite A
Bedford, TX 76022
(817) 719-2692
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) has decades of Biomedical Technologies experience  in Asia, Europe and USA.  He has authored over 200 publications and patents.  He is the Primary Investigator for major grants from National Eye Institute including  Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award.